BCTX
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.19
+5.98%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 86.4K | 117.9K | 147.9K | 82.6K | 15.5K |
| Gross Profit | (86.4K) | (117.9K) | (147.9K) | (82.6K) | (15.5K) |
| Operating Expenses | |||||
| R&D Expense | 34.1M | 29.2M | 29.5M | 27.2M | 20.5M |
| SG&A Expense | 8.0M | 6.8M | 8.1M | 6.2M | 10.6M |
| General & Admin Expense | 6.0M | 6.8M | 8.1M | 6.2M | 10.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.6M) | — | — | — | — |
| Total Operating Expenses | 39.4M | 36.1M | 37.6M | 33.3M | 31.1M |
| Cost and Expenses | 39.5M | 35.6M | 37.7M | 33.3M | 31.1M |
| Operating Income (EBIT) | (39.5M) | (35.6M) | (37.7M) | (33.3M) | (31.1M) |
| Non-Operating | |||||
| Interest Income | 584.2K | 626.0K | 166.4K | 283.6K | 1.2M |
| Interest Expense | 29.6K | — | 51.3K | — | — |
| Net Interest Income | 554.5K | 626.0K | 115.1K | 283.6K | 1.2M |
| Other Non-Op Income/Expense | 750.8K | 720.1K | 899.7K | 28.4M | 4.0M |
| Non-Operating Income (excl Interest) | (413.4K) | — | — | (28.4M) | — |
| EBT (Pre-Tax Income) | (38.7M) | (34.9M) | (36.8M) | (4.9M) | (27.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (38.3M) | (34.9M) | (36.5M) | (4.8M) | (27.1M) |
| Earnings from Cont. Ops | (38.7M) | (34.9M) | (36.8M) | (4.9M) | (27.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (38.3M) | (34.9M) | (36.5M) | (4.8M) | (27.1M) |
| Per Share | |||||
| Basic EPS | ($9.38) | ($6.97) | ($62.60) | ($43.01) | ($192.55) |
| Diluted EPS | ($9.38) | ($6.97) | ($62.60) | ($43.01) | ($195.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.7M | 5.0M | 1.9M | 1.1M | 1.0M |
| Diluted Shares Outstanding | 8.7M | 5.0M | 1.9M | 1.1M | 1.0M |
| Profitability Metrics | |||||
| EBITDA | (38.9M) | (35.5M) | (37.6M) | (4.8M) | (31.1M) |
| D&A | 119.2K | 117.9K | 107.3K | 83.9K | 15.3K |
| EBIT | (39.1M) | (35.6M) | (37.7M) | (4.9M) | (31.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026